ATE270883T1 - Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck - Google Patents

Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck

Info

Publication number
ATE270883T1
ATE270883T1 AT00921979T AT00921979T ATE270883T1 AT E270883 T1 ATE270883 T1 AT E270883T1 AT 00921979 T AT00921979 T AT 00921979T AT 00921979 T AT00921979 T AT 00921979T AT E270883 T1 ATE270883 T1 AT E270883T1
Authority
AT
Austria
Prior art keywords
activators
blood pressure
treat glaucoma
eye blood
elevated eye
Prior art date
Application number
AT00921979T
Other languages
English (en)
Inventor
Debra L Shade
Iok-Hou Pang
Abbot F Clark
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Application granted granted Critical
Publication of ATE270883T1 publication Critical patent/ATE270883T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT00921979T 1999-04-20 2000-04-07 Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck ATE270883T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13013399P 1999-04-20 1999-04-20
PCT/US2000/009503 WO2000062769A2 (en) 1999-04-20 2000-04-07 Use of ap-1 activators to treat glaucoma and ocular hypertension

Publications (1)

Publication Number Publication Date
ATE270883T1 true ATE270883T1 (de) 2004-07-15

Family

ID=22443214

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921979T ATE270883T1 (de) 1999-04-20 2000-04-07 Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck

Country Status (12)

Country Link
EP (1) EP1169026B1 (de)
JP (1) JP2002542189A (de)
AT (1) ATE270883T1 (de)
AU (1) AU766199B2 (de)
BR (1) BR0009862A (de)
CA (1) CA2369126A1 (de)
DE (1) DE60012163T2 (de)
DK (1) DK1169026T3 (de)
ES (1) ES2223502T3 (de)
HK (1) HK1039568B (de)
PT (1) PT1169026E (de)
WO (1) WO2000062769A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603964B2 (en) 2008-07-04 2013-12-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for modulating angiogenesis via dystrophin Dp71

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CN1169857A (zh) * 1996-07-10 1998-01-14 林东和 降眼压活性组合物

Also Published As

Publication number Publication date
AU4223100A (en) 2000-11-02
BR0009862A (pt) 2002-01-08
HK1039568A1 (en) 2002-05-03
EP1169026B1 (de) 2004-07-14
DE60012163D1 (de) 2004-08-19
WO2000062769A3 (en) 2001-01-04
ES2223502T3 (es) 2005-03-01
HK1039568B (en) 2004-12-10
WO2000062769A2 (en) 2000-10-26
JP2002542189A (ja) 2002-12-10
AU766199B2 (en) 2003-10-09
CA2369126A1 (en) 2000-10-26
DK1169026T3 (da) 2004-10-04
DE60012163T2 (de) 2004-11-11
EP1169026A2 (de) 2002-01-09
PT1169026E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE60101265D1 (de) Behandlung von augenschmerzen
DE60228278D1 (de) Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE60138137D1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
ATE198044T1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ATE282413T1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
ATE222488T1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE60216281D1 (de) Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
DE60222745D1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
ATE375141T1 (de) Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE69705421D1 (de) 15-fluoro-prostaglandine als augendrucksenkende mittel
ATE258793T1 (de) 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom
ATE409491T1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
ATE270883T1 (de) Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
GB0521351D0 (en) Modulation of TRPV expression levels
DE60020591D1 (de) Benzenoidderivate von 15-hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1169026

Country of ref document: EP

REN Ceased due to non-payment of the annual fee